This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information
Login or create an account to see restricted content
Login or Register- AT2D Slide library
- Cardiovascular Outcomes Trials
- SUSTAIN-6 Trial
SUSTAIN-6 Trial
SUSTAIN-6 was designed as a non-inferiority trial to assess the CV safety of semaglutide versus placebo. 1 The trial included >3000 patients with T2D who had established CV disease or were aged ≥60 years with ≥1 CV risk factor.1 This module details the CV endpoints and safety results from the trial.
SUSTAIN-6 Trial
Rate this content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
Login or create an account to see restricted content
- SUSTAIN-6 Trial
- Login or create an account to see restricted contentSUSTAIN-6: study design
- Login or create an account to see restricted contentSUSTAIN-6: baseline characteristics (1/2)
- Login or create an account to see restricted contentSUSTAIN-6: baseline characteristics (2/2)
- Login or create an account to see restricted contentSUSTAIN-6: renal function at baseline
- Login or create an account to see restricted contentSUSTAIN-6: glucose-lowering medications at baseline
- Login or create an account to see restricted contentSUSTAIN-6: CV medications at baseline (1/2)
- Login or create an account to see restricted contentSUSTAIN-6: CV medications at baseline (2/2)
- Login or create an account to see restricted contentSUSTAIN-6: primary outcome 3P-MACE
- Login or create an account to see restricted contentSUSTAIN-6: components of 3P-MACE
- Login or create an account to see restricted contentSUSTAIN-6: subgroup analysis of 3P-MACE (1/5)
- Login or create an account to see restricted contentSUSTAIN-6: subgroup analysis of 3P-MACE (2/5)
- Login or create an account to see restricted contentSUSTAIN-6: subgroup analysis of 3P-MACE (3/5)
- Login or create an account to see restricted contentSUSTAIN-6: subgroup analysis of 3P-MACE (4/5)
- Login or create an account to see restricted contentSUSTAIN-6: subgroup analysis of 3P-MACE (5/5)
- Login or create an account to see restricted contentSUSTAIN-6: CV death
- Login or create an account to see restricted contentSUSTAIN-6: non-fatal MI
- Login or create an account to see restricted contentSUSTAIN-6: non-fatal stroke
- Login or create an account to see restricted contentSUSTAIN-6: hospitalisation for heart failure
- Login or create an account to see restricted contentSUSTAIN-6: summary of all CV endpoints
- Login or create an account to see restricted contentSUSTAIN-6: microvascular endpoints
- Login or create an account to see restricted contentSUSTAIN-6: diabetic retinopathy complications
- Login or create an account to see restricted contentSUSTAIN-6: new or worsening nephropathy (1/2)
- Login or create an account to see restricted contentSUSTAIN-6: new or worsening nephropathy (2/2)
- Login or create an account to see restricted contentSUSTAIN-6: metabolic parameters (1/3)
- Login or create an account to see restricted contentSUSTAIN-6: metabolic parameters (2/3)
- Login or create an account to see restricted contentSUSTAIN-6: heart rate
- Login or create an account to see restricted contentSUSTAIN-6: metabolic parameters (3/3)
- Login or create an account to see restricted contentSUSTAIN-6: glucose-lowering medications introduced post-baseline, and hypoglycaemic events
- Login or create an account to see restricted contentSUSTAIN-6: CV medications introduced post-baseline
- Login or create an account to see restricted contentSUSTAIN-6: safety outcomes (1/2)
- Login or create an account to see restricted contentSUSTAIN-6: safety outcomes (2/2)
- Login or create an account to see restricted contentSUSTAIN-6: safety outcomes, pancreatitis or neoplasm
- Login or create an account to see restricted contentSUSTAIN-6: summary